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The role of genetics in the current diagnostic workup of
idiopathic non‐histaminergic angioedema
To the Editor,
Angioedema (AE) is a clinical syndrome characterized by recurrent
episodes of swelling mainly of skin, subcutaneous and submucosal
tissues and/or the upper respiratory tract.
Angioedema can occur along with wheals in urticaria and as
result of exposure to specific agents in allergic reactions. Non allergic
angioedema without wheals is defined as primary angioedema.1 The
Hereditary Angioedema International Working Group (HAWK)/EAACI
classification in 2014 recognized hereditary (HAE) and acquired
(AAE) forms of angioedema.2
In this classification, hereditary forms include those caused by a
deficiency of complement component 1 (C1) esterase inhibitor HAE
(C1‐INH‐HAE), the form with coagulation factor XII (FXII) mutations
(FXII‐HAE), and those with an unknown genetic cause (U‐HAE). For
the latter, a higher age at onset of disease is reported when com-
pared to C1‐INH‐HAE and FXII‐HAE.3
Among the acquired forms, ACE‐inhibitor related (ACEI‐AAE),
acquired C1 deficiency (C1‐INH‐AAE), idiopathic histaminergic (IH‐
AAE) and non‐histaminergic angioedema (InH‐AAE) can be recog-
nized, the latter being identified by clinical features, absence of an
identifiable cause of angioedema, and failure to prevent symptoms
with high‐dose antihistamine prophylaxis.
In the HAWK/EAACI classification, the etiopathogenesis of one
hereditary (U‐HAE) and one acquired (InH‐AAE) form of angioedema
still remains undefined. Considering HAE with normal C1‐INH
(U‐HAE and FXII‐HAE), the proportion of unknown is about 2/3.4
Within InH‐AAE cases, about 10% are bradykinin‐mediated and the
remaining 90% is an heterogenous group of disorders for which
there is still uncertainty on origin and pathophysiology. In these
patients, the swelling could be mediated by either mast cell media-
tors, in particular histamine, bradykinin, or by other mediators.2
Owing to the limited biomarkers available for distinguishing pri-
mary angioedema with normal C1‐INH, diagnosis of InH‐AAE relies on
an exclusion process; however, genetics could play a fundamental role.
In FXII‐HAE, disease‐causing mutations of F12 gene are transmit-
ted as an autosomal dominant trait with incomplete penetrance, and
the proportion of asymptomatic carriers is >90% in males, while it is
around 40% in females. Such an incomplete penetrance and variable
clinical presentation hinder diagnosis of FXII‐HAE.3
Recently, a large study of Lopes Veronez and colleagues high-
lighted the usefulness of F12 genetic testing to diagnose patients
presenting with HAE with normal C1‐INH, including male patients,
even in the absence of a family history or without clear estrogen
influence.5 So far, a number of studies showed that a proportion of
patients initially diagnosed as InH‐AAE was affected by FXII‐HAE
with lack of family history, with a prevalence varying from 12% to
100% across different centers (Table 1), whose data derive from dif-
ferent study designs and by patients’ ancestry.3-6
However, in several HAE patients presenting with normal C1‐INH,
no mutations in FXII gene are detectable and these patients have been
previously classified as U‐HAE. Within this latter subset of patients,
we recently discovered a causal mutation in the Angiopoietin 1
(ANGPT1) gene.7 While in the index ANGPT1‐HAE family, all A119S
mutation carriers were symptomatic and the trait clearly followed an
AD pattern; we also found another unrelated female patient classifi-
able as InH‐AAE (recurrent angioedema with non‐histaminergic fea-
tures, lack of response to high‐dose antihistamine prophylaxis and
steroids, negative family history) but bearing the same recently
described A119S ANGPT1 mutation. Although we did not have yet
the opportunity to examine the family members of this new subject, there
is an apparent lack of family history for angioedema or related symptoms.
Furthermore, Bork's group recently found a previously unre-
ported variant of the plasminogen (PLG) gene K330E, segregating
with the clinical phenotype as an AD trait among four families with
HAE and normal C1‐INH and the index patients of nine further fami-
lies, not bearing F12 mutations.8 Although the pathogenicity has
been not yet fully demonstrated by functional studies, Germenis and
colleagues found the same K330E PLG variant in 6 individuals.9 Fur-
ther five families coming from France and Japan with HAE with nor-
mal C1-INH and the PLG gene mutation have been described in this
Journal.10,11 Interestingly, in both the Bork's and Germenis’ cohorts
of PLG‐mutated patients the clinical expression of disease ranged
from asymptomatic to highly symptomatic subjects and Germenis
describes that two out of three PLG‐HAE index patients did not
have family history and had been initially identified as InH‐AAE.
Thus, for both the newly identified ANGPT1‐HAE and PLG‐HAE,
the preliminary data show that the genetic background of the dis-
ease may at first not be overt similarly to FXII‐HAE. Data in Table 1
summarize the studies with available data on the occurrence of FXII‐
HAE, PLG‐HAE, and ANGPT1‐HAE diagnosis in patients with initial
diagnosis of InH‐AAE.
Taking into account these recent data and the current definition of
InH‐AAE by exclusion of other diseases, we underscore that the screen-
ing of HAE‐associated mutations in F12, PLG, and ANGPT1 is important
in patients with angioedema of uncertain etiopathogenesis. For F12 and
PLGmutations, the ascertainment can be easily performed in most labo-
ratories by amplification and Sanger sequencing of a single exon of each
gene. As the number of reported patients for ANGPT1 is still quite small,
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a complete analysis of the gene should be performed. Of note, novel
techniques such as the applications of next‐generation sequencing may
be employed in this field in the near future.
In conclusion, we propose that the diagnosis of InH‐AAE should
be established only after genetic analysis of F12, PLG, and ANGPT1
is made. A better definition of InH‐AAE diagnosis on this basis is
fundamental for a precise definition of outcomes, evaluation of
safety, and efficacy of treatments in these subgroups of patients.
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